Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 684, Issue 1-2, 2010, Pages 106-108

  Acun, Tolga ^a   Terzioǧlu Kara, Ece ^a,b   Konu, Ozlen ^a   Ozturk, Mehmet ^a,c   Yakicier, Mustafa Cengiz ^a  

^a BILKENT UNIVERSITY   (Turkey)

^b BOGAZICI UNIVERSITY   (Turkey)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

Hepatocellular carcinoma; MDM2 SNP309; Polymorphism; TP53

Indexed keywords

GUANINE; PROTEIN MDM2; PROTEIN P53; THYMINE;

AFRICA; ALLELE; ARTICLE; CHINA; CONTROLLED STUDY; EUROPE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; JAPAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 73949092254     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.11.008     Document Type: Article

References (24)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 5 Suppl. 1 (2004) S5-S16
2. Hemminki K., and Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 52 (2003) 592-596
3. Sutton A., Nahon P., Pessayre D., Rufat P., Poire A., Ziol M., Vidaud D., Barget N., Ganne-Carrie N., Charnaux N., Trinchet J.C., Gattegno L., and Beaugrand M. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res. 66 (2006) 2844-2852
4. Vogel A., Kneip S., Barut A., Ehmer U., Tukey R.H., Manns M.P., and Strassburg C.P. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121 (2001) 1136-1144
5. Yu M.W., Yang S.Y., Chiu Y.H., Chiang Y.C., Liaw Y.F., and Chen C.J. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29 (1999) 697-702
6. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis. 19 (1999) 235-242
7. Puisieux A., and Ozturk M. TP53 and hepatocellular carcinoma. Pathol. Biol. (Paris) 45 (1997) 864-870
8. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., and Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362 (1993) 857-860
9. Momand J., Zambetti G.P., Olson D.C., George D., and Levin A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
10. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
11. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., and Levine A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
12. Bougeard G., Baert-Desurmont S., Tournier I., Vasseur S., Martin C., Brugieres L., Chompret A., Bressac-de Paillerets B., Stoppa-Lyonnet D., Bonaiti-Pellie C., and Frebourg T. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet. 43 (2006) 531-533
13. Unsal H., Yakicier C., Marcais C., Kew M., Volkmann M., Zentgraf H., Isselbacher K.J., and Ozturk M. Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 822-826
14. Cagatay T., and Ozturk M. P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene 21 (2002) 7971-7980
15. Sotamaa K., Liyanarachchi S., Mecklin J.P., Jarvinen H., Aaltonen L.A., Peltomaki P., and de la Chapelle A. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res. 11 (2005) 6840-6844
16. Foulkes A.S. Applied Statistical Genetics with R: For Population-Based Association Studies. Use R (2009), Springer
17. Cohen Y., and Cohen J.Y. Statistics and Data with R: An Applied Approach Through Examples (2008), Wiley
18. Momand J., Jung D., Wilezynski S., and Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26 (1998) 3453-3459
19. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., and Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53 (1993) 236-239
20. Sanchez-Carbayo M., Socci N.D., Kirchoff T., Erill N., Offit K., Bochner B.H., and Cordon-Cardo C. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations and poor outcome in invasive bladder cancer. Clin. Cancer Res. 13 (2007) 3215-3220
21. Bond G.L., Hu W., and Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 65 (2005) 5481-5484
22. Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., and Omata M. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res. 12 (2006) 4867-4871
23. Ezzikouri S., El Feydi A.E., Afifi R., El Kihal L., Benazzouz M., Hassar M., Marchio A., Pineau P., and Benjelloun S. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect. Prev. 32 (2009) 380-385
24. Yoon Y.J., Chang H.Y., Ahn S.H., Kim J.K., Park Y.K., Kang D.R., Park J.Y., Myoung S.M., Kim do Y., Chon C.Y., and Han K.H. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29 (2008) 1192-1196